Strategies for bringing drug delivery tools into discovery

International Journal of Pharmaceutics

Volumn 412, Issue 1-2, 2011, Pages 1-7

  Kwong, Elizabeth ^a   Higgins, John ^a   Templeton, Allen C ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alternate route of administration; Drug delivery tool in discovery; In vivo model development; Mechanism based toxicity; Nanoparticles; Target delivery

Indexed keywords

2,4 DINITROPHENOL; CELLULOSE; CHITOSAN; DODECYL SULFATE SODIUM; GLYCOPROTEIN P; HYDROXYL PROPYL CELLULOSE; METHYLCELLULOSE; UNCLASSIFIED DRUG;

DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FORMULATION; DRUG INDUSTRY; DRUG METABOLISM; DRUG TOXICITY; MICRONUCLEUS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; BIOMEDICAL RESEARCH; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; ORGANIZATIONAL CASE STUDIES;

EID: 79957445181     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.03.024     Document Type: Review

References (27)

1. C.A. Bailey, A. Railkar, and R. Tarantino Along the development superhighway: at the interface between discovery and development of small molecule therapeutics Am. Chem. Soc. 211 1996 12 (Abstract papers)
2. B. Booth, R. Glassman, and P. Ma Oncology trials Nat. Rev. Drug Discov. 2 2003 609 610
3. M.V. Chaubal Application of formulation technologies in lead candidate selection and optimization DDT 9 14 2004 603 609 (Pubitemid 38900510)
4. J.A. DiMasi, R.W. Hansen, and H.G. Grabowski The price of innovation: new estimates of drug development costs J. Health Econ. 22 2003 151 185 (Pubitemid 36279392)
5. K.E. Driscoll Intratracheal instillation as an exposure technique for the evaluation of respiratory tract toxicity: uses and limitations Toxicol. Sci. 55 2000 24 35 (Pubitemid 30252432)
6. Innovation or Stagnation? Challenge and Opportunity on the Critical Path to New Medical Products 2004 US Department of Health and Human Services. Food and Drug Administration http://www.fda.gov/oc/initiatives/criticalpath/ whitepaper.pdf (accessed 31.10.06)
7. C.J. Fearn The world pharmaceutical market Presented at the "Strategic Management Review" IMS Health, Australia, 19-20 June 2000
8. S.C. Gad Nonclinical vehicle use in studies by multiple routes in multiple species Int. J. Toxicol. 25 2006 499 521 (Pubitemid 44888807)
9. L. Illum Transport of drugs from the nasal cavity to central nervous system Eur. J. Pharm. Sci. 11 2000 1 18 (Pubitemid 30410839)
10. K. Ismail, and L. John Can the pharmaceutical industry reduce attrition rates? Nat. Rev. 3 2004 711 715
11. J.-Y. Jung Enhanced solubility and dissolution rate of itraconazole by a solid dispersion technique Int. J. Pharm. 187 1999 209 218 (Pubitemid 29443901)
12. C. Leuner, and J. Dressman Improving drug solubility for oral delivery using solid dispersions Eur. J. Pharm. Biopharm. 50 2000 47 60 (Pubitemid 30326688)
13. P. Li, and L. Zhao Developing early formulations: practice and perspective Int. J. Pharm. 341 2007 1 19 (Pubitemid 47088122)
14. J. Maas, W. Kamm, and G. Hauck An integrated early formulation strategy from hit evaluation to preclinical candidate profiling Eur. J. Pharm. Biopharm. 66 2007 1 10 (Pubitemid 46412973)
15. Crawford, Mark, 2010. State of the Industry 2010. News Magazine, April, pp. 34-39.
16. J.D. Moser Enhancing bioavailability of poorly soluble drugs using spray dried solid dispersions - part I Am. Pharm. Rev. September-October 2008 68 71
17. J.D. Moser Enhancing bioavailability of poorly soluble drugs using spray dried solid dispersions Am. Pharm. Rev. November/December 2008 60 78
18. B. Munos Lessons from 60 years of pharmaceutical innovation Nat. Rev. Drug Discov. 8 December 2009 959 968
19. T. Niwa, and N. Hashimoto Novel technology to prepare oral formulations for preclinical safety studies Int. J. Pharm. 350 2008 70 78
20. A.S. Railkar The discovery-development interface: early formulation strategies for poorly soluble small molecule therapeutic Pharm. Res. 13 1996 S-278
21. S.L. Roberds BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimer's disease therapeutics Hum. Mol. Genet. 10 2001 1317 1324 (Pubitemid 32600485)
22. V. Saxena, R. Panicucci, Y. Joshi, and S. Garad Developability assessment in pharmaceutical industry: an integrated group approach for selecting developable candidates J. Pharm. Sci. 98 6 2009 1962 1979
23. A. Shanbhag Methods for screening of solid dispersion formulations of low-solubility compounds - miniaturization and automation of solvent casting and dissolution testing Int. J. Pharm. 351 2008 209 218 (Pubitemid 351186860)
24. R.G. Strickley Formulation in drug discovery Annu. Rep. Med. Chem. 43 2008 419 451
25. S. Venkatesh, and R.A. Lipper Role of the development scientist in compound lead selection and optimization J. Pharm. Sci. 89 2 2000 145 154 (Pubitemid 30120795)
26. A.G.E. Wilson A New paradigm for improving oral absorption of drugs in discovery: role of physicochemical properties, different excipients and the pharmaceutical scientist Future Med. Chem. 2 1 2010 1 5
27. K. Yamada Right delivery for poorly BBB-permeable CNS drugs: nose to brain (olfactory) delivery of TS-002, prostaglandin D2 analogue Control. Release Soc. Newslett. 24 2007 11 12